New Oral PCSK9 Inhibitor Cuts Bad Cholesterol by 58% in Genetic High Cholesterol
Enlicitide, a daily pill, dramatically reduced LDL cholesterol in patients with familial hypercholesterolemia beyond what statins alone achieved.
Summary
A breakthrough oral medication called enlicitide reduced dangerous LDL cholesterol by 58% in people with familial hypercholesterolemia, a genetic condition causing extremely high cholesterol levels. This Phase 3 trial of 303 adults showed the daily pill worked far better than placebo when added to existing statin therapy. Participants taking enlicitide saw their bad cholesterol drop from an average of 119 mg/dL, while placebo users saw minimal change. The drug also reduced other harmful lipids including apolipoprotein B and lipoprotein(a). Most importantly, enlicitide was well-tolerated with similar side effects to placebo. This represents a major advance for people with genetic high cholesterol who struggle to reach safe levels despite maximum statin therapy.
Detailed Summary
People with familial hypercholesterolemia face a lifelong battle against dangerously high cholesterol due to genetic mutations affecting cholesterol metabolism. Despite maximum statin therapy, many cannot reach safe cholesterol levels, leaving them at extreme risk for heart attacks and strokes.
Researchers tested enlicitide, an oral PCSK9 inhibitor, in 303 adults with this genetic condition across 59 international sites. Participants were randomly assigned to receive either 20mg enlicitide daily or placebo for 52 weeks, while continuing their existing statin therapy. The average starting LDL cholesterol was 119 mg/dL.
Results were remarkable: enlicitide reduced LDL cholesterol by 58% at 24 weeks compared to just 2.6% with placebo. This massive 59% difference persisted at one year. The drug also cut apolipoprotein B by 48%, non-HDL cholesterol by 52%, and lipoprotein(a) by 25% - all key markers of cardiovascular risk. Importantly, side effects were similar between groups, suggesting excellent tolerability.
For longevity optimization, this represents a paradigm shift. PCSK9 inhibitors were previously only available as expensive injections, limiting accessibility. An effective oral option could democratize access to this powerful cholesterol-lowering class. The dramatic reductions achieved suggest potential benefits even for people without genetic hypercholesterolemia who want to minimize cardiovascular aging.
However, this study focused specifically on familial hypercholesterolemia patients. Whether enlicitide provides similar benefits in the general population remains unknown, and long-term cardiovascular outcomes data is still needed.
Key Findings
- Enlicitide reduced LDL cholesterol by 58% versus 2.6% with placebo at 24 weeks
- Benefits persisted at one year with 55% LDL reduction versus 9% placebo increase
- Drug also cut apolipoprotein B by 48% and lipoprotein(a) by 25%
- Side effects were similar to placebo, suggesting excellent safety profile
- 96.7% of participants completed the full 52-week trial
Methodology
Phase 3 randomized controlled trial of 303 adults with familial hypercholesterolemia conducted at 59 sites across 17 countries. Participants received enlicitide 20mg daily or placebo for 52 weeks while continuing statin therapy.
Study Limitations
Study limited to patients with familial hypercholesterolemia, so results may not apply to general population. Long-term cardiovascular outcomes data not yet available, and cost-effectiveness compared to injectable PCSK9 inhibitors unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.